Clinical Trials
14 trialsNCT01384513 2026-04-15
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT00255346 2025-12-30
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04761822 2025-08-12
SARS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT00038675 2022-01-04
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
M.D. Anderson Cancer Center
Phase NA Completed
NCT00814073 2019-12-03
AB06006
AB Science
Phase 3 Completed
NCT02808793 2019-03-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Allakos Inc.
Phase 1 Completed
NCT00831974 2018-12-11
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
AB Science
Phase 2 Completed
NCT01266369 2018-12-10
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
AB Science
Phase 2 Completed
NCT00006413 2017-07-02
Stem Cell Transplantation to Treat Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT01481909 2016-11-03
SMART
Charite University, Berlin, Germany
Phase 2/3 Completed
NCT02478957 2016-09-29
Treatment of Indolent Systemic Mastocytosis With PA101
Patara Pharma
Phase 2 Completed
NCT01297777 2016-08-29
Imatinib in KIT-negative Systemic Mastocytosis
Hospital Virgen de la Salud
Phase 4 Completed
NCT01333293 2016-01-18
XOLMA
University of Zurich
Phase 2/3 Completed